Clinical Trial: NCT02747004
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Eli Lilly and Company |
| Information Provided By: | Eli Lilly and Company |
| Last Update Posted: | 2026-10-16 |
Study Overview
Brief Summary
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer.
Official Title
A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Intervention / Treatment
- Drug: Abemaciclib
- Drug: Tamoxifen
- Drug: Prophylactic Loperamide
Other Study ID Numbers
- 16339
- I3Y-MC-JPCG
- 2016-000288-18
- 2016
Start Date (Actual)
2016-09-14
Primary Completion Date (Actual)
2018-06-15
Study Completion Date (Actual)
2026-09-09
Enrollment (Actual)
234
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Eli Lilly and Company |
| Information Provided By: | Eli Lilly and Company |
| Last Update Posted: | 2026-10-16 |
Study Overview
Brief Summary
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer.
Official Title
A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Intervention / Treatment
- Drug: Abemaciclib
- Drug: Tamoxifen
- Drug: Prophylactic Loperamide
Other Study ID Numbers
- 16339
- I3Y-MC-JPCG
- 2016-000288-18
- 2016
Start Date (Actual)
2016-09-14
Primary Completion Date (Actual)
2018-06-15
Study Completion Date (Actual)
2026-09-09
Enrollment (Actual)
234
Study Type
Interventional
Phase
Phase 2